A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days (Q69962091)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

title

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

main subject

phase I clinical trial

1 reference

P J Creaven

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

D E Brenner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

J W Cowens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

R P Huben

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

R M Wolf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

H Takita

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

S G Arbuck

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

M S Razack

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

A D Proefrock

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

publication date

1 January 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

7 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

7 October 2019

page(s)

186-191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2924376 AND SRC:MED&resulttype=core&format=json

Phase I study of recombinant tumor necrosis factor in cancer patients.

7 October 2019

cites work

1 reference

12 December 2020

Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial

1 reference

12 December 2020

Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

1 reference

12 December 2020

Phase I clinical trial of recombinant human tumor necrosis factor

1 reference

12 December 2020

Phase I study of recombinant human tumor necrosis factor

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism

1 reference

12 December 2020